URISPAS Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Urispas, and when can generic versions of Urispas launch?
Urispas is a drug marketed by Ortho Mcneil Janssen and is included in one NDA.
The generic ingredient in URISPAS is flavoxate hydrochloride. There are eight drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the flavoxate hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Urispas
A generic version of URISPAS was approved as flavoxate hydrochloride by PADAGIS US on December 16th, 2004.
Summary for URISPAS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 101 |
| Clinical Trials: | 2 |
| Patent Applications: | 1,012 |
| DailyMed Link: | URISPAS at DailyMed |
Recent Clinical Trials for URISPAS
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mahidol University | Phase 4 |
| Padagis LLC | Phase 1 |
| Paddock Laboratories, Inc. | Phase 1 |
Anatomical Therapeutic Chemical (ATC) Classes for URISPAS
US Patents and Regulatory Information for URISPAS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ortho Mcneil Janssen | URISPAS | flavoxate hydrochloride | TABLET;ORAL | 016769-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
